Keyphrases
11-oxygenated Androgens
21%
21-Hydroxylase Deficiency (21OHD)
17%
Adverse Events
50%
AZD7762
19%
Checkpoint Kinase 1 (CHK1)
27%
Circulating Tumor Cells
29%
Comorbidity
17%
Confidence Interval
22%
COVID-19
51%
COVID-19 Vaccine
30%
Durvalumab
29%
Effector T Cells
21%
Enhancer of Zeste Homolog 2 (EZH2)
20%
Esophageal Cancer
21%
Esophagectomy
31%
Excision
19%
Fitness Factor
28%
Gemcitabine
44%
Glioma
32%
High Risk
24%
Homologous Recombination Repair
22%
Hospitalized Patients
22%
Immunohistochemistry
23%
In Cancer
22%
Inflammation
20%
Klebsiella Pneumoniae (K. pneumoniae)
34%
Lung Adenocarcinoma
24%
Myeloid-derived Suppressor Cells
17%
Non-small Cell Lung Cancer (NSCLC)
25%
Overall Survival
41%
Pancreatic Cancer
35%
Pancreatic Cancer Cells
26%
Pathologist
17%
Phase II Study
20%
Poor Prognosis
24%
Primary Aldosteronism
17%
Programmed Death-ligand 1 (PD-L1)
20%
Progression-free Survival
25%
Radiosensitization
30%
Simulation Study
17%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
18%
Stage III Non-small Cell Lung Cancer
29%
Survival Analysis
19%
Survival Endpoint
17%
T Cells
19%
Targeted Therapy
21%
Tumor
78%
Tumor Immunity
18%
Vaccine Adverse Event Reporting System (VAERS)
23%
Vaccine Adverse Events
19%
Medicine and Dentistry
5 (3 Fluorophenyl) N (3 Piperidinyl) 3 Ureido 2 Thiophenecarboxamide
16%
Adverse Event
33%
Androgen
19%
Biological Marker
65%
Biopsy Technique
25%
Breast Carcinoma
20%
Cancer Cell
24%
Checkpoint Kinase 1
17%
Chemoradiotherapy
16%
Chemotherapy
20%
Circulating Tumor Cell
25%
Comorbidity
18%
COVID-19
48%
COVID-19 Vaccine
18%
Diagnosis
23%
Diseases
39%
Esophageal Cancer
21%
Esophagectomy
43%
Estrogen Receptor
16%
Ganglioglioma
45%
Gemcitabine
26%
Homologous Recombination
15%
Hydrocortisone
15%
Immunity
18%
Immunohistochemistry
21%
Immunotherapy
27%
Lung Cancer
20%
Malignant Neoplasm
40%
Mastectomy
14%
Melanoma
28%
Neoplasm
100%
Non Small Cell Lung Cancer
42%
Overall Survival
37%
Pancreas Cancer
34%
Pathologist
17%
Pediatrics
13%
Primary Hyperaldosteronism
17%
Progesterone Receptor
16%
Progression Free Survival
17%
Quality of Life
14%
Radiosensitization
18%
Recombination Repair
15%
Recurrent Disease
23%
Sensitization
18%
Steroid 21 Monooxygenase Deficiency
17%
Surgery
16%
T Cell
15%
Tetracosactide
18%
Thorax Surgery
16%
Urokinase Receptor
15%